RS51140B - Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa - Google Patents
Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensaInfo
- Publication number
- RS51140B RS51140B YUP-708/03A YUP70803A RS51140B RS 51140 B RS51140 B RS 51140B YU P70803 A YUP70803 A YU P70803A RS 51140 B RS51140 B RS 51140B
- Authority
- RS
- Serbia
- Prior art keywords
- alkoxy
- alkyl
- phenyl
- amino
- substituted
- Prior art date
Links
- 150000002461 imidazolidines Chemical class 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- -1 methylenedioxy, ethylenedioxy Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Jedinjenje formule I, naznačeno time,što jeA, ciklopropilmetil- ili izobutil; E je -CO-R6, -CO-H ili -CH2-OR7; Z je kiseonik ili sumpor; R1 je vodonik ili metil;R2 je fenil, piridil ili (C1-C4)-alkil, pri čemu je alkil ostatak koji može biti supstituisan jednim ili više atomima fluora, a fenil ostatak može biti supstituisan jednim ili više identičnih ili različitih supstituenata odabranih iz grupe koju čine (C1-C4)-alkil, (C1-C4)-alkoksi, metilendioksi, etilendioksi, halogen, trifiuorometil i trifiuorometoksi; R3 i R4 su metil ili trifluormetil;R5 je vodonik ili (C1-C4)-alkil, pri čemu je alkil ostatak koji može biti supstituisan jednim ili više atomima fluora;R6 je hidroksil, (C1-C10)-alkoksi, fenil-(C1-C8)-alkoksi, feniloksi, (C1-C8)-alkilkarboniloksi- (C1-C6)-alkoksi, fenilkarboniloksi-(C1-C6)-alkoksi, fenil-(C1-C6)-alkilkarboniloksi-(C1-C6)-alkoksi, (C1-C8)-alkoksikarboniloksi-(C1-C6)-alkoksi, feniloksikarboniloksi-(C1-C6)-alkoksi, fenil-(C1-C6)-alkoksikarboniloksi-(C1-C6)-alkoksi, amino, mono ((C1-C10)-alkil)amino ili di((C1-C10)-alkil)amino; R7 je vodonik ili (C1-C4)-alkil;i svi njihovi steroizomerni oblici i njihove smeše u svim odnosima, i njihovi fiziološki prihvatljive soli.Prijava sadrži još 15 patentnih zahteva.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10111877A DE10111877A1 (de) | 2001-03-10 | 2001-03-10 | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU70803A YU70803A (sh) | 2006-05-25 |
| RS51140B true RS51140B (sr) | 2010-10-31 |
Family
ID=7677184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YUP-708/03A RS51140B (sr) | 2001-03-10 | 2002-02-23 | Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6680333B2 (sr) |
| EP (1) | EP1373249B1 (sr) |
| JP (1) | JP4482277B2 (sr) |
| KR (1) | KR100991678B1 (sr) |
| CN (1) | CN1227248C (sr) |
| AR (1) | AR035692A1 (sr) |
| AT (1) | ATE293621T1 (sr) |
| AU (1) | AU2002233358B2 (sr) |
| BG (1) | BG108134A (sr) |
| BR (1) | BR0207981A (sr) |
| CA (1) | CA2440648C (sr) |
| CZ (1) | CZ301893B6 (sr) |
| DE (2) | DE10111877A1 (sr) |
| DK (1) | DK1373249T3 (sr) |
| EE (1) | EE05401B1 (sr) |
| ES (1) | ES2240687T3 (sr) |
| HR (1) | HRP20030713B1 (sr) |
| HU (1) | HU228304B1 (sr) |
| IL (2) | IL157830A0 (sr) |
| ME (1) | MEP61108A (sr) |
| MX (1) | MXPA03007634A (sr) |
| MY (1) | MY129029A (sr) |
| NO (1) | NO326001B1 (sr) |
| NZ (1) | NZ528075A (sr) |
| PE (1) | PE20020904A1 (sr) |
| PL (1) | PL204622B1 (sr) |
| PT (1) | PT1373249E (sr) |
| RS (1) | RS51140B (sr) |
| RU (1) | RU2303592C2 (sr) |
| SI (1) | SI1373249T1 (sr) |
| SK (1) | SK286652B6 (sr) |
| TW (1) | TWI328587B (sr) |
| WO (1) | WO2002072573A1 (sr) |
| ZA (1) | ZA200306107B (sr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19647380A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| HRP20010766A2 (en) * | 1999-03-22 | 2002-12-31 | Ortho Mcneil Pharm Inc | Process of preparing 3s-3-amino-3-aryl propionic acid and derivatives thereof |
| WO2005034953A1 (ja) * | 2003-10-10 | 2005-04-21 | Kowa Co., Ltd. | 血管新生抑制薬 |
| US20090275529A1 (en) * | 2008-05-05 | 2009-11-05 | Reiss Allison B | Method for improving cardiovascular risk profile of cox inhibitors |
| LT3722808T (lt) | 2010-10-25 | 2024-12-27 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumo, koreliuojančio su skirtumais svcam ir/arba smadcam lygiuose, nustatymo būdai |
| CN112707874A (zh) * | 2020-12-29 | 2021-04-27 | 广东中科药物研究有限公司 | 一种抗病毒化合物及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4009506A1 (de) | 1990-03-24 | 1991-09-26 | Hoechst Ag | Hydantoinderivate |
| DE4126277A1 (de) | 1991-08-08 | 1993-02-11 | Cassella Ag | Hydantoinderivate |
| WO1993013798A1 (en) | 1992-01-13 | 1993-07-22 | Biogen, Inc. | Treatment for asthma |
| AU674302B2 (en) | 1992-02-12 | 1996-12-19 | Biogen Idec Ma Inc. | Treatment for inflammatory bowel disease |
| DE4207254A1 (de) | 1992-03-07 | 1993-09-09 | Cassella Ag | 4-oxo-2-thioxoimidazolidin-derivate |
| DE4213634A1 (de) | 1992-04-24 | 1993-10-28 | Cassella Ag | 2,4-Dioxo-imidazolidin-Derivate |
| DE4224414A1 (de) | 1992-07-24 | 1994-01-27 | Cassella Ag | Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung |
| DE4228717A1 (de) | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidin-Derivate |
| CA2153228A1 (en) | 1993-01-08 | 1994-07-21 | Shiu-Lan Ng Chiang | Peptide inhibitors of cell adhesion |
| AU688751B2 (en) | 1993-01-12 | 1998-03-19 | Biogen Idec Ma Inc. | Recombinant anti-VLA4 antibody molecules |
| CA2155303C (en) | 1993-02-09 | 2010-04-20 | Linda C. Burkly | Treatment for insulin dependent diabetes |
| DE4308034A1 (de) | 1993-03-13 | 1994-09-15 | Cassella Ag | Neue Heterocyclen, ihre Herstellung und ihre Verwendung |
| DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| ES2424292T3 (es) | 1994-01-25 | 2013-09-30 | Biogen Idec Ma Inc. | Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4 |
| EP0767674A4 (en) | 1994-06-29 | 1999-06-16 | Texas Biotechnology Corp | METHOD FOR INHIBITING THE BINDING OF INTEGRIN ALPHA 4 BETA 1 TO VCAM-1 OR FIBRONECTIN |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| DE19515177A1 (de) | 1995-04-28 | 1996-10-31 | Cassella Ag | Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| EP0796855B1 (de) | 1996-03-20 | 2002-02-06 | Hoechst Aktiengesellschaft | Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| WO1998004913A1 (en) | 1996-07-25 | 1998-02-05 | Biogen, Inc. | Molecular model for vla-4 inhibitors |
| DE19647382A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
| DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CN1327443A (zh) | 1997-10-31 | 2001-12-19 | 艾文蒂斯药品有限公司 | 取代的酰苯胺化合物 |
| GB9723789D0 (en) * | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
| DE19751251A1 (de) * | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
| DE19821483A1 (de) * | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| UA66864C2 (uk) * | 1998-06-30 | 2004-06-15 | Пфайзер Продактс Інк. | Похідні сечовини, фармацевтична композиція і спосіб лікування або профілактики запальних, аутоімунних або респіраторних захворювань |
| AU1915399A (en) | 1998-07-10 | 2000-02-01 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| DE19922462A1 (de) * | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
-
2001
- 2001-03-10 DE DE10111877A patent/DE10111877A1/de not_active Withdrawn
-
2002
- 2002-02-23 JP JP2002571489A patent/JP4482277B2/ja not_active Expired - Fee Related
- 2002-02-23 KR KR1020037011940A patent/KR100991678B1/ko not_active Expired - Fee Related
- 2002-02-23 HU HU0303455A patent/HU228304B1/hu not_active IP Right Cessation
- 2002-02-23 DK DK02700268T patent/DK1373249T3/da active
- 2002-02-23 NZ NZ528075A patent/NZ528075A/en not_active IP Right Cessation
- 2002-02-23 WO PCT/EP2002/001917 patent/WO2002072573A1/en active IP Right Grant
- 2002-02-23 IL IL15783002A patent/IL157830A0/xx unknown
- 2002-02-23 RU RU2003129986/04A patent/RU2303592C2/ru not_active IP Right Cessation
- 2002-02-23 PL PL362573A patent/PL204622B1/pl unknown
- 2002-02-23 AT AT02700268T patent/ATE293621T1/de active
- 2002-02-23 ME MEP-611/08A patent/MEP61108A/xx unknown
- 2002-02-23 RS YUP-708/03A patent/RS51140B/sr unknown
- 2002-02-23 PT PT02700268T patent/PT1373249E/pt unknown
- 2002-02-23 CA CA2440648A patent/CA2440648C/en not_active Expired - Fee Related
- 2002-02-23 HR HR20030713A patent/HRP20030713B1/xx not_active IP Right Cessation
- 2002-02-23 EE EEP200300436A patent/EE05401B1/xx not_active IP Right Cessation
- 2002-02-23 DE DE60203791T patent/DE60203791T2/de not_active Expired - Lifetime
- 2002-02-23 SI SI200230124T patent/SI1373249T1/xx unknown
- 2002-02-23 CZ CZ20032429A patent/CZ301893B6/cs not_active IP Right Cessation
- 2002-02-23 ES ES02700268T patent/ES2240687T3/es not_active Expired - Lifetime
- 2002-02-23 EP EP02700268A patent/EP1373249B1/en not_active Expired - Lifetime
- 2002-02-23 CN CNB028063147A patent/CN1227248C/zh not_active Expired - Fee Related
- 2002-02-23 MX MXPA03007634A patent/MXPA03007634A/es active IP Right Grant
- 2002-02-23 SK SK1126-2003A patent/SK286652B6/sk not_active IP Right Cessation
- 2002-02-23 BR BR0207981-0A patent/BR0207981A/pt active Search and Examination
- 2002-02-23 AU AU2002233358A patent/AU2002233358B2/en not_active Ceased
- 2002-03-07 AR ARP020100830A patent/AR035692A1/es active IP Right Grant
- 2002-03-08 US US10/092,901 patent/US6680333B2/en not_active Expired - Lifetime
- 2002-03-08 PE PE2002000184A patent/PE20020904A1/es not_active Application Discontinuation
- 2002-03-08 MY MYPI20020824A patent/MY129029A/en unknown
- 2002-03-08 TW TW091104327A patent/TWI328587B/zh not_active IP Right Cessation
-
2003
- 2003-08-07 ZA ZA200306107A patent/ZA200306107B/en unknown
- 2003-08-25 BG BG108134A patent/BG108134A/bg unknown
- 2003-09-09 NO NO20033981A patent/NO326001B1/no not_active IP Right Cessation
- 2003-09-09 IL IL157830A patent/IL157830A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04001240A (es) | Analogos antitumorales. | |
| HRP20020175B1 (hr) | N-heterociklički derivati kao inhibitori nos | |
| NL350075I2 (sr) | ||
| BRPI0616799B8 (pt) | derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor | |
| MEP24608A (en) | Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same | |
| DE60130771D1 (de) | Substituierte heterocyclische amide | |
| MEP25608A (en) | Derivatives of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| CA2318349A1 (en) | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | |
| MY146669A (en) | Pyrazole derivatives for treating hiv | |
| RS20050182A (en) | Derivatives of dioxane-2-alkyl carbamates,preparation method thereof and application of same in therapeutics | |
| BR0111263A (pt) | Derivados de 2-aminocarbonil-9h-purina | |
| RS52562B (sr) | (3-aril-piperazin-1-il) derivati 6,7-dialkoksikvinazolina, 6,7- dialkoksiftalazina i 6,7-dialkoksiizokvinolina | |
| MXPA05011411A (es) | 1,4-diazepinas sustituidas y usos de las mismas. | |
| MEP12708A (en) | Derivatives of n-[phenyl (alkylpiperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| RS51200B (sr) | (imidazol-1-il-metil)-piridazin kao blokator nmda receptora | |
| PL368409A1 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a? receptor and their use as medicaments | |
| RS50829B (sr) | Novi oligosaharidi, njihova proizvodnja i farmaceutske kompozicije sa sadržajem istih | |
| ATE356624T1 (de) | Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung | |
| HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
| RS51190B (sr) | Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti | |
| BRPI0417345A (pt) | compostos inibidores de quìnase baseados em azola, composições e seus usos | |
| HRP20080119T3 (en) | Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| HRP20040230B1 (hr) | Agonisti muskarina | |
| RS51140B (sr) | Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa |